Michael W N Deininger

Michael W N Deininger

UNVERIFIED PROFILE

Are you Michael W N Deininger?   Register this Author

Register author
Michael W N Deininger

Michael W N Deininger

Publications by authors named "Michael W N Deininger"

Are you Michael W N Deininger?   Register this Author

59Publications

1257Reads

36Profile Views

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Nat Rev Cancer 2017 06;17(7):425-440

INSERM U1170, Gustave Roussy, Faculté de médecine Paris-Sud, Université Paris-Saclay, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2017.40DOI Listing
June 2017

Systemic mastocytosis in a patient with Cowden syndrome.

Am J Hematol 2014 Dec 27;89(12):1154. Epub 2014 Aug 27.

Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23815DOI Listing
December 2014

Selection of therapy: rational decisions based on molecular events.

Hematol Oncol Clin North Am 2011 Oct;25(5):1009-23, vi

Deininger Lab, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4270, Salt Lake City, UT 84112-5550, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2011.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251311PMC
October 2011

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

Clin Cancer Res 2011 Jan 22;17(2):212-21. Epub 2010 Nov 22.

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-3314DOI Listing
January 2011

A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.

Cancer Res 2010 Sep 31;70(18):7325-35. Epub 2010 Aug 31.

Ben May Department for Cancer Research, Committees on Developmental Biology, Genetics, Cancer Biology, and Cell Physiology, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940946PMC
September 2010

Management of early stage disease.

Hematology Am Soc Hematol Educ Program 2005 :174-82

Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Mail Code L592, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2005.1.174DOI Listing
November 2009

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.

Blood 2007 Oct 11;110(7):2242-9. Epub 2007 May 11.

Howard Hughes Medical Institute, Chevy Chase, MD, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2007-03-06
Publisher Site
http://dx.doi.org/10.1182/blood-2007-03-066936DOI Listing
October 2007

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.

Clin Cancer Res 2007 Oct;13(20):6136-43

Department of Pathology, Center for Hematologic Malignancies, Cancer Institute, and Howard Hughes Medical Institute, Oregon Health & Science University, Portland, Oregon 97201, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-07-1112DOI Listing
October 2007

Optimizing therapy of chronic myeloid leukemia.

Exp Hematol 2007 Apr;35(4 Suppl 1):144-54

Oregon Health and Science University, Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2007.01.023DOI Listing
April 2007

Characterization of murine JAK2V617F-positive myeloproliferative disease.

Cancer Res 2006 Dec;66(23):11156-65

Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-06-2210DOI Listing
December 2006

Chronic myeloid leukemia in 2006: a perspective.

Haematologica 2006 Feb;91(2):152

View Article

Download full-text PDF

Source
February 2006

BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?

Cell Cycle 2005 Dec 19;4(12):1761-6. Epub 2005 Dec 19.

Department of Hematology/Oncology, University of Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cc.4.12.2261DOI Listing
December 2005

Can we afford to let sleeping dogs lie?

Blood 2005 Mar;105(5):1840-1

Oregon Health and Science University, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2004-12-4764DOI Listing
March 2005

AMN107: tightening the grip of imatinib.

Cancer Cell 2005 Feb;7(2):117-9

Howard Hughes Medical Institute, Oregon Health &Science University Cancer Institute, Portland, Oregon, 97239, USA.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S153561080500035
Publisher Site
http://dx.doi.org/10.1016/j.ccr.2005.01.020DOI Listing
February 2005

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

Blood 2004 Dec 10;104(12):3754-7. Epub 2004 Aug 10.

Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://www.bloodjournal.org/cgi/doi/10.1182/blood-2004-06-21
Publisher Site
http://dx.doi.org/10.1182/blood-2004-06-2189DOI Listing
December 2004

Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.

Blood 2004 Nov 8;104(9):2912-8. Epub 2004 Jul 8.

Howard Hughes Medical Institute, Oregon Health and Science University Cancer Institute, Portland 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2003-05-1669DOI Listing
November 2004

SRCircumventing imatinib resistance.

Cancer Cell 2004 Aug;6(2):108-10

Oregon Health & Science University Cancer Institute, Center for Hematologic Malignancies, L592, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2004.08.006DOI Listing
August 2004

Biology of chronic myelogenous leukemia--signaling pathways of initiation and transformation.

Hematol Oncol Clin North Am 2004 Jun;18(3):545-68, vii-viii

Department of Haematology, Imperial College, London & Hammersmith Hospital, Du Cane Road, London W12 0NN, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2004.03.008DOI Listing
June 2004

Basic science going clinical: molecularly targeted therapy of chronic myelogenous leukemia.

J Cancer Res Clin Oncol 2004 Feb 7;130(2):59-72. Epub 2003 Nov 7.

BMT/Leukemia Center, Oregon Health & Science University, 3181 SW Sam Jackson Park Road L592, Portland 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-003-0502-2DOI Listing
February 2004

c-CBL is not required for leukemia induction by Bcr-Abl in mice.

Oncogene 2003 Dec;22(55):8852-60

Department of Cell and Developmental Biology, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1206892DOI Listing
December 2003

Specific targeted therapy of chronic myelogenous leukemia with imatinib.

Pharmacol Rev 2003 Sep 17;55(3):401-23. Epub 2003 Jul 17.

BMT/Leukemia Center, Oregon Health and Science University, Mailcode L592, 3181 S.W. Sam Jackson Park Road, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1124/pr.55.3.4DOI Listing
September 2003

Practical management of patients with chronic myeloid leukemia receiving imatinib.

J Clin Oncol 2003 Apr 13;21(8):1637-47. Epub 2003 Mar 13.

Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2003.11.143DOI Listing
April 2003

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

Semin Hematol 2003 Apr;40(2 Suppl 2):26-30

School of Clinical and Laboratory Sciences, The Medical School, University of Newcastle, Newcastle, UK.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S003719630380778
Publisher Site
http://dx.doi.org/10.1053/shem.2003.50058DOI Listing
April 2003

Cytogenetic studies in patients on imatinib.

Semin Hematol 2003 Apr;40(2 Suppl 2):50-5

Bone Marrow Transplant/Leukemia Center, Oregon Health and Sciences University, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/shem.2003.50043DOI Listing
April 2003